Julia Conley, staff writer
New documents reveal Monsanto's 'fusion center' aimed at targeting and discrediting journalists and critics
Julia Conley, staff writer
"A big win for solidarity with all people on the move...and against the...
Jessica Corbett, staff writer
"It is our responsibility to ban this poison from our environment."


Up there in the annals of multinational corporations doing heinous things in the name of obscene profits comes the German-based Bayer's response to India ending the pharma giant's monopoly for a pricey new anti-cancer drug, thus allowing a small Indian company to make a generic version that poor sick people can afford. A year of Bayer's Nexavar costs $96,000 in the U.S. and $69,000 in India, 41 times the per capita income; India's Natco Ltd. made it for $177 a year. Outraged Bayer officials...